----
Current ValuationThe current P/E ratio is 62.28, within the reasonable range, cheaper than 36.15% of the time in the past 1 years, and the industry ranks 53/256, the industry Median -1.16.
62.28xP/E
$92.99Stock price
$1.49Earnings per share
62.28xP/E
Stock price$92.99Earnings per share$1.49
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 56.49x
- Typical range
- 38.74x–138.08x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0295887116
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TEVAUSTeva Pharmaceutical Industries | 68.50x | 38.33% | $48.36B |
SDZNYUSSANDOZ GROUP AG SPON ADS EACH REP 1 COM SHS | 62.28x | -- | $40.23B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
